PAK2 and hepatocellular carcinoma: For example, the nonselective TKI lenvatinib is thought to inhibit FGFR with feedback activation of the EGFR–PAK2–ERK5 signaling axis, while the combination of lenvatinib and the EGFR inhibitor gefitinib has been found to be clinically meaningful in patients with advanced HCC.311